Suppr超能文献

用于经前烦躁障碍的选择性5-羟色胺再摄取抑制剂

SSRIs for premenstrual dysphoric disorder.

出版信息

Drug Ther Bull. 2002 Sep;40(9):70-2. doi: 10.1136/dtb.2002.40970.

Abstract

Around 2-10% of women have premenstrual symptoms that severely disrupt daily living. When such symptoms are dominated by severe disturbances of mood and behaviour, the condition has been named premenstrual dysphoric disorder (PMDD). Fluoxetine, a selective serotonin re-uptake inhibitor (SSRI), is licensed in the UK for the treatment of PMDD. Here, we discuss the diagnosis of PMDD and the evidence for the efficacy of fluoxetine and other SSRIs in its treatment.

摘要

约2%至10%的女性有经前症状,严重影响日常生活。当这些症状以严重的情绪和行为障碍为主时,这种情况被称为经前烦躁障碍(PMDD)。氟西汀是一种选择性5-羟色胺再摄取抑制剂(SSRI),在英国被批准用于治疗PMDD。在此,我们讨论PMDD的诊断以及氟西汀和其他SSRI治疗PMDD有效性的证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验